Managing blood pressure and heart risks during BTKi treatment
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of blood cancer: CLL, mantle cell lymphoma, Waldenstrom macroglobulinemia, or marginal zone lymphoma.
- You are about to start treatment with a medication called a Bruton tyrosine kinase inhibitor (BTKi), or switch to a new one after a 5-day break.
- You are willing to return to the Mayo Clinic for regular check-ups during the study.
- Your cancer has not spread to your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using a connected blood pressure monitor at home can help manage blood pressure in people starting a BTK inhibitor (a type of targeted therapy for blood cancers). Participation may help detect and manage high blood pressure early, which is a known side effect of these drugs.
This study looks at what happens to patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after they stop taking a type of targeted therapy called a BTK inhibitor. It aims to understand treatment patterns and outcomes to help guide future care.
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
This observational study tracks how your heart rhythm (heartbeat pattern) changes while you take a BTK inhibitor or venetoclax. It may help doctors better understand heart rhythm risks in people receiving these cancer-related medicines.
This study looks at whether certain blood cancer treatments increase the risk of an irregular heartbeat called atrial fibrillation. It may help doctors understand which patients need closer heart monitoring.
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.